June 26th 2025
Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.
A Visible Disease with Invisible Pain: Mona Shahriari Discusses Suicide Risk in Atopic Dermatitis
June 25th 2025Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.
Johann Gudjonsson, MD, PhD, on Emerging AD Therapies: From Single Targets to Combination Approaches
June 19th 2025RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.
Real Cases, Key Takeaways: Applying Atopic Dermatitis Insights in Clinical Practice
June 9th 2025Panelist discusses how patient cases demonstrate the importance of considering nonsteroidal agents in patients of color (due to hypopigmentation risks) and elderly patients (due to skin thinning), concluding that effective atopic dermatitis management requires proper moisturizing, appropriate corticosteroid cycling, and proactive twice-weekly maintenance with newer nonsteroidal topicals to prevent long-term complications.
Stronger Together: Collaborating With Dermatologists for Better Outcomes
June 9th 2025Panelist discusses how referral to dermatology should occur when patients fail to reach treatment goals despite proper skincare, appropriate topical steroid and nonsteroid use, and proactive treatment, emphasizing the importance of maintaining open dialogue about systemic therapy options rather than dismissing them as “last resort” treatments.
Tailoring Treatment: Personalizing Topical Therapy for Patients With Atopic Dermatitis
June 9th 2025Panelist discusses how topical treatment selection should be based on affected body areas, patient preferences for vehicle type, and disease extent, noting that patients prefer topical over systemic therapies and emphasizing the importance of using specialty pharmacies with manufacturer contracts to ensure affordable access through proper prior authorization processes.
Beyond Steroids: Clinical Trial Results on the Next Generation Agents for Atopic Dermatitis
June 9th 2025nonsteroidal topicals including roflumilast (next-generation PDE4 inhibitor), ruxolitinib (JAK1/2 inhibitor), and tapinarof (aryl hydrocarbon receptor agonist) offer significant improvements in efficacy and tolerability compared with older agents like crisaborole, with clinical trial data showing 30% to 50% of patients achieving complete or near-complete clearance.